Schroder Investment Management Group lowered its stake in Flexion Therapeutics, Inc. (NASDAQ:FLXN) by 33.3% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 394,014 shares of the specialty pharmaceutical company’s stock after selling 196,764 shares during the period. Schroder Investment Management Group owned about 1.24% of Flexion Therapeutics worth $10,670,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of FLXN. Bank of New York Mellon Corp boosted its position in shares of Flexion Therapeutics by 9.0% in the first quarter. Bank of New York Mellon Corp now owns 2,124,208 shares of the specialty pharmaceutical company’s stock valued at $57,163,000 after buying an additional 175,879 shares during the last quarter. Novo A S boosted its position in shares of Flexion Therapeutics by 27.3% in the fourth quarter. Novo A S now owns 1,397,718 shares of the specialty pharmaceutical company’s stock valued at $26,585,000 after buying an additional 300,000 shares during the last quarter. Kingdon Capital Management L.L.C. boosted its position in shares of Flexion Therapeutics by 29.2% in the fourth quarter. Kingdon Capital Management L.L.C. now owns 1,379,486 shares of the specialty pharmaceutical company’s stock valued at $26,238,000 after buying an additional 311,865 shares during the last quarter. State Street Corp boosted its position in shares of Flexion Therapeutics by 27.6% in the fourth quarter. State Street Corp now owns 391,606 shares of the specialty pharmaceutical company’s stock valued at $7,449,000 after buying an additional 84,770 shares during the last quarter. Finally, Pictet Asset Management Ltd. bought a new position in shares of Flexion Therapeutics during the first quarter valued at about $7,323,000. Institutional investors own 75.35% of the company’s stock.

Institutional Ownership by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Shares of Flexion Therapeutics, Inc. (NASDAQ FLXN) opened at 18.08 on Wednesday. The firm’s 50 day moving average is $18.11 and its 200 day moving average is $20.42. The firm’s market capitalization is $574.17 million. Flexion Therapeutics, Inc. has a 1-year low of $13.20 and a 1-year high of $29.41.

Flexion Therapeutics (NASDAQ:FLXN) last announced its earnings results on Thursday, May 4th. The specialty pharmaceutical company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.73) by $0.02. Analysts anticipate that Flexion Therapeutics, Inc. will post ($3.72) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Schroder Investment Management Group Cuts Stake in Flexion Therapeutics, Inc. (FLXN)” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at https://www.thecerbatgem.com/2017/06/21/schroder-investment-management-group-has-10-67-million-position-in-flexion-therapeutics-inc-flxn-updated-updated.html.

Several analysts recently commented on FLXN shares. Cantor Fitzgerald set a $40.00 price target on shares of Flexion Therapeutics and gave the company a “buy” rating in a research report on Thursday, May 4th. Royal Bank Of Canada set a $44.00 price objective on shares of Flexion Therapeutics and gave the stock a “buy” rating in a research report on Sunday, March 26th. Janney Montgomery Scott restated a “buy” rating and set a $30.00 price objective on shares of Flexion Therapeutics in a research report on Saturday, March 11th. Needham & Company LLC restated a “buy” rating and set a $34.00 price objective on shares of Flexion Therapeutics in a research report on Monday, May 15th. Finally, Zacks Investment Research upgraded shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, March 14th. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has given a strong buy rating to the company. Flexion Therapeutics currently has a consensus rating of “Buy” and an average price target of $30.60.

In other Flexion Therapeutics news, CFO Frederick W. Driscoll sold 3,000 shares of the stock in a transaction dated Thursday, March 23rd. The stock was sold at an average price of $23.00, for a total value of $69,000.00. Following the transaction, the chief financial officer now owns 10,777 shares of the company’s stock, valued at $247,871. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Mark Stejbach purchased 1,580 shares of the company’s stock in a transaction dated Friday, June 16th. The shares were acquired at an average cost of $17.02 per share, for a total transaction of $26,891.60. The disclosure for this purchase can be found here. Corporate insiders own 18.00% of the company’s stock.

About Flexion Therapeutics

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Receive News & Stock Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related stocks with our FREE daily email newsletter.